India, Feb. 2 -- India's pharma sector hit Rs 4.72 lakh crore turnover in FY25, fueled by 8.4% domestic market growth to Rs 2.25 lakh crore, led by cardiac (10.8%), GI (10.2%), and anti-diabetic therapies. Exports soared 9.3% to $30.5 billion, cementing its status as the world's third-largest by volume and pharmacy to the globe.

With a market capitalisation of Rs 20,144.76 crore, the shares of Piramal Pharma Ltd were trading at Rs 151.45 per share, decreasing around 0.10 percent as compared to the previous closing price of Rs 151.60 apiece.

Brokerage Recommendations ICICI Direct has issued a strong 'Buy' recommendation on the pharma stock, setting a target price of Rs 230, which suggests a potential upside of 52% from its current level ...